Novartis halts development of Ionis heart drug after late‑stage trial failure
Novartis announced it will stop work on pelacarsen, an antisense therapy discovered by Ionis, after the drug failed to meet its primary endpoint in the late‑stage Lp(a)HORIZON trial. The trial, run in September, was aimed at reducing cardiovascular events linked to lipoprotein(a). Novartis said it will keep testing the molecule for calcific aortic valve stenosis, but the heart‑disease program is being abandoned.
Why it matters
The termination removes a potential new revenue source from Novartis' cardiovascular pipeline and may weigh on the company's near‑term growth outlook. Ionis loses a partner for a high‑profile indication, which could affect its future collaboration prospects.
Key facts
- 1Novartis will halt development of pelacarsen, an antisense heart drug discovered by Ionis. tradingview.com
- 2Pelacarsen failed to meet its primary endpoint in the Lp(a)HORIZON late‑stage trial. tradingview.com
- 3The trial was conducted in September. seekingalpha.com
- 4Novartis will continue testing pelacarsen for calcific aortic valve stenosis. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.